Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

3 terminated/withdrawn out of 12 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

17%

2 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

8(72.7%)

Phase 3

2(18.2%)

Phase 2

1(9.1%)

11Total

Phase 1(8)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT06056297Phase 3Recruiting

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

Role: lead

NCT04154488Phase 1Completed

A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders

Role: lead

NCT03995108Phase 3Active Not Recruiting

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Role: lead

NCT06914869Phase 1Completed

Drug-Drug Interaction Potential of Mavorixafor

Role: lead

NCT06858696Phase 1Recruiting

A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function

Role: lead

NCT03005327Phase 2Completed

A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

Role: lead

NCT02667886Phase 1Completed

Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma

Role: lead

NCT04274738Phase 1Completed

A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4

Role: lead

NCT02923531Phase 1Terminated

Addition of X4P-001 to Nivolumab Treatment in Participants With Renal Cell Carcinoma

Role: lead

NCT02823405Phase 1Completed

X4P-001 and Pembrolizumab in Patients With Advanced Melanoma

Role: lead

NCT02680782Phase 1Terminated

A Study Comparing Once-Daily vs. Twice-Daily Dosing of X4P-001 in Healthy Volunteers

Role: lead

NCT03087370Withdrawn

A Retrospective and Prospective Natural History Study of Patients With WHIM Syndrome

Role: lead

All 12 trials loaded